Reported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027

Benzinga · 2d ago
  • Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO
  • Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027